Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy
BACKGROUND: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. METHODS: T...
Saved in:
Published in | Cancer Vol. 116; no. 23; pp. 5517 - 5526 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.12.2010
Wiley-Blackwell |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BACKGROUND:
Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation.
METHODS:
Tissue microarrays were constructed from 132 cystectomies (1994‐2002). Immunohistochemistry was performed for Pten, c‐myc, p27, phosphorylated (phos)Akt, phosS6, and 4E‐BP1. Markers were evaluated for pattern, percentage, and intensity of staining.
RESULTS:
Mean length of follow‐up was 62.6 months (range, 1‐182 months). Disease progression, overall survival (OS), and disease‐specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E‐BP1. Pten, p27, phosAkt, phosS6, and 4E‐BP1 expression correlated with pathologic stage (pathological stage; P<.03). Pten, 4E‐BP1, and phosAkt expression correlated with divergent aggressive histology and invasion. phosS6 expression inversely predicted OS (P = .01), DSS (P = .001), and progression (P = .05). c‐myc expression inversely predicted progression (P = .01). In a multivariate analysis model that included TNM stage grouping, divergent aggressive histology, concomitant carcinoma in situ, phosS6, and c‐myc expression, phosS6 was an independent predictor of DSS (P = .03; hazard ratio [HR], −0.19), whereas c‐myc was an independent predictor of progression (P = .02; HR, −0.38). In a second model substituting organ‐confined disease and lymph node status for TNM stage grouping, phosS6 and c‐myc remained independent predictors of DSS (P = .03; HR, −0.21) and progression (P = .03; HR, −0.34), respectively.
CONCLUSIONS:
We found an overall down‐regulation of mTOR pathway in bladder urothelial carcinoma. phosS6 independently predicted DSS, and c‐myc independently predicted progression. Cancer 2010. © 2010 American Cancer Society.
Mammalian target of rapamycin pathway was overall down‐regulated in urothelial carcinoma. Phosphorylated S6 protein was an independent predictor of disease‐specific survival, and c‐myc was an independent predictor of progression. |
---|---|
AbstractList | BACKGROUND: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. METHODS: Tissue microarrays were constructed from 132 cystectomies (1994-2002). Immunohistochemistry was performed for Pten, c-myc, p27, phosphorylated (phos)Akt, phosS6, and 4E-BP1. Markers were evaluated for pattern, percentage, and intensity of staining. RESULTS: Mean length of follow-up was 62.6 months (range, 1-182 months). Disease progression, overall survival (OS), and disease-specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E-BP1. Pten, p27, phosAkt, phosS6, and 4E-BP1 expression correlated with pathologic stage (pathological stage; PP = .01), DSS (P = .001), and progression (P = .05). c-myc expression inversely predicted progression (P = .01). In a multivariate analysis model that included TNM stage grouping, divergent aggressive histology, concomitant carcinoma in situ, phosS6, and c-myc expression, phosS6 was an independent predictor of DSS (P = .03; hazard ratio [HR], -0.19), whereas c-myc was an independent predictor of progression (P = .02; HR, -0.38). In a second model substituting organ-confined disease and lymph node status for TNM stage grouping, phosS6 and c-myc remained independent predictors of DSS (P = .03; HR, -0.21) and progression (P = .03; HR, -0.34), respectively. CONCLUSIONS: We found an overall down-regulation of mTOR pathway in bladder urothelial carcinoma. phosS6 independently predicted DSS, and c-myc independently predicted progression. Cancer 2010. ? 2010 American Cancer Society. Abstract BACKGROUND: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. METHODS: Tissue microarrays were constructed from 132 cystectomies (1994‐2002). Immunohistochemistry was performed for Pten, c‐ myc , p27, phosphorylated (phos)Akt, phosS6, and 4E‐BP1. Markers were evaluated for pattern, percentage, and intensity of staining. RESULTS: Mean length of follow‐up was 62.6 months (range, 1‐182 months). Disease progression, overall survival (OS), and disease‐specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E‐BP1. Pten, p27, phosAkt, phosS6, and 4E‐BP1 expression correlated with pathologic stage (pathological stage; P <.03). Pten, 4E‐BP1, and phosAkt expression correlated with divergent aggressive histology and invasion. phosS6 expression inversely predicted OS ( P = .01), DSS ( P = .001), and progression ( P = .05). c‐ myc expression inversely predicted progression ( P = .01). In a multivariate analysis model that included TNM stage grouping, divergent aggressive histology, concomitant carcinoma in situ, phosS6, and c‐ myc expression, phosS6 was an independent predictor of DSS ( P = .03; hazard ratio [HR], −0.19), whereas c‐ myc was an independent predictor of progression ( P = .02; HR, −0.38). In a second model substituting organ‐confined disease and lymph node status for TNM stage grouping, phosS6 and c‐ myc remained independent predictors of DSS ( P = .03; HR, −0.21) and progression ( P = .03; HR, −0.34), respectively. CONCLUSIONS: We found an overall down‐regulation of mTOR pathway in bladder urothelial carcinoma. phosS6 independently predicted DSS, and c‐ myc independently predicted progression. Cancer 2010. © 2010 American Cancer Society. Mammalian target of rapamycin pathway was overall down‐regulated in urothelial carcinoma. Phosphorylated S6 protein was an independent predictor of disease‐specific survival, and c‐ myc was an independent predictor of progression. BACKGROUNDBladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. METHODSTissue microarrays were constructed from 132 cystectomies (1994-2002). Immunohistochemistry was performed for Pten, c-myc, p27, phosphorylated (phos)Akt, phosS6, and 4E-BP1. Markers were evaluated for pattern, percentage, and intensity of staining. RESULTSMean length of follow-up was 62.6 months (range, 1-182 months). Disease progression, overall survival (OS), and disease-specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E-BP1. Pten, p27, phosAkt, phosS6, and 4E-BP1 expression correlated with pathologic stage (pathological stage; P<.03). Pten, 4E-BP1, and phosAkt expression correlated with divergent aggressive histology and invasion. phosS6 expression inversely predicted OS (P=.01), DSS (P=.001), and progression (P=.05). c-myc expression inversely predicted progression (P=.01). In a multivariate analysis model that included TNM stage grouping, divergent aggressive histology, concomitant carcinoma in situ, phosS6, and c-myc expression, phosS6 was an independent predictor of DSS (P=.03; hazard ratio [HR], -0.19), whereas c-myc was an independent predictor of progression (P=.02; HR, -0.38). In a second model substituting organ-confined disease and lymph node status for TNM stage grouping, phosS6 and c-myc remained independent predictors of DSS (P=.03; HR, -0.21) and progression (P=.03; HR, -0.34), respectively. CONCLUSIONSWe found an overall down-regulation of mTOR pathway in bladder urothelial carcinoma. phosS6 independently predicted DSS, and c-myc independently predicted progression. BACKGROUND: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. METHODS: Tissue microarrays were constructed from 132 cystectomies (1994‐2002). Immunohistochemistry was performed for Pten, c‐myc, p27, phosphorylated (phos)Akt, phosS6, and 4E‐BP1. Markers were evaluated for pattern, percentage, and intensity of staining. RESULTS: Mean length of follow‐up was 62.6 months (range, 1‐182 months). Disease progression, overall survival (OS), and disease‐specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E‐BP1. Pten, p27, phosAkt, phosS6, and 4E‐BP1 expression correlated with pathologic stage (pathological stage; P<.03). Pten, 4E‐BP1, and phosAkt expression correlated with divergent aggressive histology and invasion. phosS6 expression inversely predicted OS (P = .01), DSS (P = .001), and progression (P = .05). c‐myc expression inversely predicted progression (P = .01). In a multivariate analysis model that included TNM stage grouping, divergent aggressive histology, concomitant carcinoma in situ, phosS6, and c‐myc expression, phosS6 was an independent predictor of DSS (P = .03; hazard ratio [HR], −0.19), whereas c‐myc was an independent predictor of progression (P = .02; HR, −0.38). In a second model substituting organ‐confined disease and lymph node status for TNM stage grouping, phosS6 and c‐myc remained independent predictors of DSS (P = .03; HR, −0.21) and progression (P = .03; HR, −0.34), respectively. CONCLUSIONS: We found an overall down‐regulation of mTOR pathway in bladder urothelial carcinoma. phosS6 independently predicted DSS, and c‐myc independently predicted progression. Cancer 2010. © 2010 American Cancer Society. Mammalian target of rapamycin pathway was overall down‐regulated in urothelial carcinoma. Phosphorylated S6 protein was an independent predictor of disease‐specific survival, and c‐myc was an independent predictor of progression. Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. Tissue microarrays were constructed from 132 cystectomies (1994-2002). Immunohistochemistry was performed for Pten, c-myc, p27, phosphorylated (phos)Akt, phosS6, and 4E-BP1. Markers were evaluated for pattern, percentage, and intensity of staining. Mean length of follow-up was 62.6 months (range, 1-182 months). Disease progression, overall survival (OS), and disease-specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E-BP1. Pten, p27, phosAkt, phosS6, and 4E-BP1 expression correlated with pathologic stage (pathological stage; P<.03). Pten, 4E-BP1, and phosAkt expression correlated with divergent aggressive histology and invasion. phosS6 expression inversely predicted OS (P=.01), DSS (P=.001), and progression (P=.05). c-myc expression inversely predicted progression (P=.01). In a multivariate analysis model that included TNM stage grouping, divergent aggressive histology, concomitant carcinoma in situ, phosS6, and c-myc expression, phosS6 was an independent predictor of DSS (P=.03; hazard ratio [HR], -0.19), whereas c-myc was an independent predictor of progression (P=.02; HR, -0.38). In a second model substituting organ-confined disease and lymph node status for TNM stage grouping, phosS6 and c-myc remained independent predictors of DSS (P=.03; HR, -0.21) and progression (P=.03; HR, -0.34), respectively. We found an overall down-regulation of mTOR pathway in bladder urothelial carcinoma. phosS6 independently predicted DSS, and c-myc independently predicted progression. |
Author | Hicks, Jessica Neilsen, Matthew E. Jadallah, Sana Schoenberg, Mark Netto, George J. Albadine, Roula Gonzalgo, Mark L. Sidransky, David Chen, Ying‐Bei DeMarzo, Angelo M. Schultz, Luciana |
Author_xml | – sequence: 1 givenname: Luciana surname: Schultz fullname: Schultz, Luciana – sequence: 2 givenname: Roula surname: Albadine fullname: Albadine, Roula – sequence: 3 givenname: Jessica surname: Hicks fullname: Hicks, Jessica – sequence: 4 givenname: Sana surname: Jadallah fullname: Jadallah, Sana – sequence: 5 givenname: Angelo M. surname: DeMarzo fullname: DeMarzo, Angelo M. – sequence: 6 givenname: Ying‐Bei surname: Chen fullname: Chen, Ying‐Bei – sequence: 7 givenname: Matthew E. surname: Neilsen fullname: Neilsen, Matthew E. – sequence: 8 givenname: Mark L. surname: Gonzalgo fullname: Gonzalgo, Mark L. – sequence: 9 givenname: David surname: Sidransky fullname: Sidransky, David – sequence: 10 givenname: Mark surname: Schoenberg fullname: Schoenberg, Mark – sequence: 11 givenname: George J. surname: Netto fullname: Netto, George J. email: gnetto1@jhmi.edu |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23438165$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20939013$$D View this record in MEDLINE/PubMed |
BookMark | eNp90cuKFDEUBuAgI07P6MYHkGxEEWrMpW5ZSjNeYFAQBXfFqdRJT6SStEmKsV7FpzVtt7qbTW5854TDf0HOfPBIyFPOrjhj4rX2Ol6JpmHiAdlwprqK8VqckQ1jrK-aWn47JxcpfS_XTjTyETkXTEnFuNyQX9c_9xFTssHTlCEviYKf6D6GnQ8pW02T3XlrrAavkQZDHTgHswVPM8Qd5sNbhD24VVtP95Bv72ClDt2IMdHytMSQb7FUzFRDLCg4OBQt0XqIKx1nmCaMFEwuq15TRp2DWx-ThwbmhE9O-yX5-vb6y_Z9dfPp3Yftm5tK10qKauwV9Fg3rZmg7VgzATTI23GSUE4TguHYMwQlTN-A7vnEsZaqnUbTKtS1vCQvjn3L0D8WTHlwNmmcZ_AYljT0XHDJhGqLfHmv5Ix3qmVdqwp9daQ6hpQimmEfrSvjFjQcUhsOqQ1_Uiv42anvMjqc_tG_MRXw_AQgaZhNLGHY9N_JWva8bYrjR3dnZ1zv-XLYftx-Pn7-G7cStgo |
CODEN | CANCAR |
CitedBy_id | crossref_primary_10_5858_arpa_2011_0471_RA crossref_primary_10_1097_MOU_0b013e32834956d6 crossref_primary_10_1111_apm_12398 crossref_primary_10_1038_nrurol_2011_193 crossref_primary_10_1016_j_path_2012_08_003 crossref_primary_10_1186_s13046_017_0626_x crossref_primary_10_1111_his_12209 crossref_primary_10_1016_j_humpath_2012_02_011 crossref_primary_10_1111_j_1464_410X_2011_10839_x crossref_primary_10_1016_j_biopha_2020_111077 crossref_primary_10_1097_PAP_0b013e3182863f80 crossref_primary_10_1053_j_semdp_2013_11_005 crossref_primary_10_1530_ERC_11_0010 crossref_primary_10_1111_j_1464_410X_2012_11569_x crossref_primary_10_1007_s00428_018_2302_8 crossref_primary_10_1038_s41698_019_0083_4 crossref_primary_10_1016_j_prp_2016_02_008 crossref_primary_10_1038_onc_2015_515 crossref_primary_10_1016_j_ctrv_2011_10_007 crossref_primary_10_1016_j_jaad_2013_04_027 crossref_primary_10_1097_MOU_0b013e328356ad0e crossref_primary_10_1111_his_12338 crossref_primary_10_1016_j_urology_2012_09_007 crossref_primary_10_3389_fonc_2019_00466 crossref_primary_10_1016_j_humpath_2012_07_009 crossref_primary_10_1016_j_humpath_2015_07_024 crossref_primary_10_1093_carcin_bgs025 crossref_primary_10_1101_cshperspect_a036293 crossref_primary_10_1016_j_urology_2014_07_050 crossref_primary_10_4111_kju_2011_52_7_466 crossref_primary_10_3727_096504017X14957929842972 crossref_primary_10_5858_2010_0727_RAIR_1 crossref_primary_10_3892_ol_2014_2392 crossref_primary_10_1080_23808993_2016_1208049 crossref_primary_10_1002_jcb_27318 crossref_primary_10_1007_s13277_015_4678_2 crossref_primary_10_1016_j_acup_2014_12_002 crossref_primary_10_1016_j_urology_2012_04_032 crossref_primary_10_1016_j_juro_2017_06_096 crossref_primary_10_1111_j_1464_410X_2011_10706_x crossref_primary_10_1016_j_clgc_2014_07_010 crossref_primary_10_1016_j_juro_2014_08_106 crossref_primary_10_1016_j_urolonc_2014_02_003 crossref_primary_10_1038_s41598_018_24526_5 crossref_primary_10_1158_0008_5472_CAN_10_3072 crossref_primary_10_1371_journal_pone_0026131 crossref_primary_10_1016_j_urolonc_2013_08_005 crossref_primary_10_1016_j_humpath_2024_04_012 crossref_primary_10_1186_s42047_018_0023_6 crossref_primary_10_1111_cas_14334 crossref_primary_10_1016_j_humpath_2012_11_026 crossref_primary_10_1155_2017_6794150 crossref_primary_10_1016_j_humpath_2013_07_008 crossref_primary_10_1016_j_urolonc_2016_05_031 crossref_primary_10_1016_j_critrevonc_2013_08_008 |
Cites_doi | 10.1016/j.eururo.2004.04.008 10.1002/cncr.22195 10.1111/j.1464-410X.2004.04574.x 10.1159/000094819 10.1007/s00428-007-0370-2 10.1042/BST0370217 10.1038/ng.371 10.1007/s12032-009-9201-4 10.1111/j.1464-410X.2007.06927.x 10.1016/S0092-8674(02)00808-5 10.1038/nrc1697 10.1097/MOU.0b013e3282f1c5c1 10.1038/nrc1974 10.1038/nrc2501 10.4161/cc.1.6.263 10.1038/sj.bjc.6601741 10.1101/gad.1212704 10.1200/JCO.2001.19.3.666 10.1158/0008-5472.CAN-09-1689 10.1128/MCB.26.10.3955-3965.2006 10.1080/03008880802291915 10.1038/onc.2009.14 10.1002/mc.20420 10.1002/cncr.22677 10.1111/j.1478-3231.2008.01798.x 10.1159/000170878 10.1158/1078-0432.CCR-09-0898 10.1159/000085933 10.4161/cc.8.9.8215 10.1136/jcp.2007.050666 10.1038/ng.370 10.1101/gad.1772909 10.1016/j.juro.2006.09.038 10.1016/j.juro.2009.08.115 10.1158/0008-5472.CAN-05-1986 10.1038/modpathol.2009.1 10.1038/sj.onc.1208002 10.1507/endocrj.50.77 10.1016/j.bbapap.2007.09.008 10.1016/S0014-5793(99)00185-4 10.1158/1078-0432.CCR-04-0941 10.1038/modpathol.3800525 |
ContentType | Journal Article |
Copyright | Copyright © 2010 American Cancer Society 2015 INIST-CNRS Copyright © 2010 American Cancer Society. |
Copyright_xml | – notice: Copyright © 2010 American Cancer Society – notice: 2015 INIST-CNRS – notice: Copyright © 2010 American Cancer Society. |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7U1 7U2 C1K 7X8 |
DOI | 10.1002/cncr.25502 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Risk Abstracts Safety Science and Risk Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Risk Abstracts Safety Science and Risk Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Risk Abstracts CrossRef MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-0142 |
EndPage | 5526 |
ExternalDocumentID | 10_1002_cncr_25502 20939013 23438165 CNCR25502 |
Genre | article Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: P50 CA058236 – fundername: NCI NIH HHS grantid: P01 CA077664 – fundername: NCI NIH HHS grantid: P01 CA077664-10 |
GroupedDBID | --- -~X .3N .GA .Y3 05W 0R~ 10A 1CY 1L6 1OC 24P 29B 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AARRQ AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEIGN AEIMD AENEX AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AGNAY AHBTC AIACR AIAGR AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C1A C45 CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HF~ HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LMP LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SJN SUPJJ TEORI UDS UHB V2E V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XPP XV2 Z0Y ZGI ZZTAW ~IA ~WT .GJ 08R 3O- AAJUZ AAUGY AAVGM ABCVL ABHUG ABPTK ABWRO ACCFJ ACXME ADAWD ADDAD AEEZP AEQDE AFFNX AFVGU AGJLS AI. AIWBW AJBDE AKALU EMOBN H~9 IQODW J5H NEJ OHT RSU VH1 WHG XFK Y6R YQJ ZA5 ZXP CGR CUY CVF ECM EIF NPM AAQOH AAYXX CITATION 7U1 7U2 C1K 7X8 |
ID | FETCH-LOGICAL-c4932-b89a8e456fda6705daa5e16bd3aaa5deaf1e80ea92f85ac81d1e4396dbf69ec43 |
IEDL.DBID | DR2 |
ISSN | 0008-543X 1097-0142 |
IngestDate | Thu Aug 15 22:41:43 EDT 2024 Fri Aug 16 07:15:02 EDT 2024 Fri Aug 23 00:55:50 EDT 2024 Sat Sep 28 07:57:50 EDT 2024 Sun Oct 22 16:08:42 EDT 2023 Sat Aug 24 01:04:09 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 23 |
Keywords | KIP1 Gene Prognosis c-myc Transitional cell carcinoma Cancerology phosS6 Urinary bladder Surgery PTEN Gene Protooncogene Tumor suppressor gene Urinary system disease Akt protein kinase Urinary tract disease Malignant tumor Akt Pten Baldder transitional cell carcinoma Cystectomy Treatment urothelial carcinoma Urinary system p27 C-Onc gene Mammalian target of rapamycin bladder myc Gene Bladder disease 4E-BP1 Cancer |
Language | English |
License | CC BY 4.0 Copyright © 2010 American Cancer Society. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4932-b89a8e456fda6705daa5e16bd3aaa5deaf1e80ea92f85ac81d1e4396dbf69ec43 |
Notes | Fax: (443) 287‐3818 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
OpenAccessLink | https://europepmc.org/articles/pmc3568488?pdf=render |
PMID | 20939013 |
PQID | 1017960769 |
PQPubID | 23462 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_812130296 proquest_miscellaneous_1017960769 crossref_primary_10_1002_cncr_25502 pubmed_primary_20939013 pascalfrancis_primary_23438165 wiley_primary_10_1002_cncr_25502_CNCR25502 |
PublicationCentury | 2000 |
PublicationDate | 1 December 2010 |
PublicationDateYYYYMMDD | 2010-12-01 |
PublicationDate_xml | – month: 12 year: 2010 text: 1 December 2010 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken – name: Hoboken, NJ – name: United States |
PublicationTitle | Cancer |
PublicationTitleAlternate | Cancer |
PublicationYear | 2010 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley-Blackwell |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley-Blackwell |
References | 2009; 23 2009; 22 2009; 69 2009; 41 2002; 110 2006; 77 2008; 18 2007; 100 2004; 23 2008; 38 2004; 46 2002; 1 2006; 6 2006; 19 2008; 8 2010; 183 2004; 90 2003; 50 2007; 109 1999; 446 1996; 56 2009; 29 2009; 28 2004; 10 2009; 56 2010; 27 2006; 86 2008; 1784 2004; 93 2004; 18 2006; 66 2005; 103 2008; 29 2007; 177 1999; 59 2007; 450 2006; 26 2001; 19 2005; 5 2008; 47 2008; 218 2005; 75 2009; 8 2008; 61 2006; 107 2009; 37 2009; 15 2005; 14 12733712 - Endocr J. 2003 Feb;50(1):77-83 10100614 - FEBS Lett. 1999 Mar 5;446(1):55-9 19453019 - Hepatogastroenterology. 2009 Jan-Feb;56(89):6-10 16341149 - Mod Pathol. 2006 Feb;19(2):238-45 12150925 - Cell. 2002 Jul 26;110(2):163-75 19913255 - J Urol. 2010 Jan;183(1):68-75 17555476 - BJU Int. 2007 Aug;100(2):259-63 16110317 - Nat Rev Cancer. 2005 Sep;5(9):713-25 17033215 - Urol Int. 2006;77(3):255-63 17964232 - Biochim Biophys Acta. 2008 Jan;1784(1):150-8 19843858 - Cancer Res. 2009 Nov 1;69(21):8256-64 18090481 - Curr Opin Urol. 2008 Jan;18(1):1-8 18815930 - Scand J Urol Nephrol Suppl. 2008 Sep;(218):154-65 17222615 - J Urol. 2007 Feb;177(2):481-7; discussion 487 17265080 - Virchows Arch. 2007 Mar;450(3):321-8 18288642 - Mol Carcinog. 2008 Sep;47(9):678-85 19396167 - Nat Genet. 2009 May;41(5):524-6 18715846 - Ann Clin Lab Sci. 2008 Summer;38(3):195-209 15083183 - Br J Cancer. 2004 Apr 19;90(8):1543-50 15623621 - Clin Cancer Res. 2004 Dec 15;10(24):8421-5 18492014 - Liver Int. 2009 Mar;29(3):399-405 15542899 - Methods Mol Med. 2005;103:89-101 17440983 - Cancer. 2007 Jun 1;109(11):2257-67 19143635 - Biochem Soc Trans. 2009 Feb;37(Pt 1):217-22 19234517 - Oncogene. 2009 Apr 2;28(13):1594-604 11157016 - J Clin Oncol. 2001 Feb 1;19(3):666-75 19342893 - Cell Cycle. 2009 May 1;8(9):1344-51 19396168 - Nat Genet. 2009 May;41(5):619-24 Cancer. 2011 Nov 1;117(21):5021 12548012 - Cell Cycle. 2002 Nov-Dec;1(6):394-400 18846101 - Nat Rev Cancer. 2008 Nov;8(11):851-64 18984977 - Tumour Biol. 2008;29(5):311-22 16488991 - Cancer Res. 2006 Feb 15;66(4):1929-39 15286700 - Oncogene. 2004 Sep 23;23(44):7378-90 19261747 - Genes Dev. 2009 Mar 15;23(6):675-80 16648488 - Mol Cell Biol. 2006 May;26(10):3955-65 14678387 - BJU Int. 2004 Jan;93(1):143-50 19789314 - Clin Cancer Res. 2009 Oct 1;15(19):6008-17 16142350 - Oncol Rep. 2005 Oct;14(4):909-13 10397272 - Cancer Res. 1999 Jul 1;59(13):3245-50 17064593 - Zhonghua Yi Xue Za Zhi. 2006 Jul 25;86(28):1970-4 19494855 - Mod Pathol. 2009 Jun;22 Suppl 2:S70-95 15245814 - Eur Urol. 2004 Aug;46(2):200-8 8752154 - Cancer Res. 1996 Sep 1;56(17):3895-7 16123561 - Urol Int. 2005;75(2):102-6 16915295 - Nat Rev Cancer. 2006 Sep;6(9):729-34 16983702 - Cancer. 2006 Oct 15;107(8):1801-11 19301157 - Med Oncol. 2010 Jun;27(2):255-61 15314020 - Genes Dev. 2004 Aug 15;18(16):1926-45 17908805 - J Clin Pathol. 2008 May;61(5):658-64 e_1_2_7_5_2 Sgambato A (e_1_2_7_48_2) 1999; 59 e_1_2_7_3_2 e_1_2_7_9_2 e_1_2_7_7_2 e_1_2_7_19_2 e_1_2_7_17_2 e_1_2_7_15_2 e_1_2_7_13_2 e_1_2_7_41_2 e_1_2_7_11_2 e_1_2_7_43_2 e_1_2_7_45_2 e_1_2_7_47_2 e_1_2_7_26_2 e_1_2_7_49_2 e_1_2_7_28_2 Okada T (e_1_2_7_18_2) 2009; 56 Fedor HL (e_1_2_7_10_2) 2005; 103 e_1_2_7_50_2 e_1_2_7_25_2 e_1_2_7_23_2 e_1_2_7_31_2 Palit V (e_1_2_7_44_2) 2005; 14 e_1_2_7_21_2 e_1_2_7_33_2 e_1_2_7_35_2 e_1_2_7_37_2 e_1_2_7_39_2 Feng W (e_1_2_7_14_2) 2008; 38 e_1_2_7_4_2 e_1_2_7_2_2 e_1_2_7_8_2 e_1_2_7_6_2 e_1_2_7_16_2 e_1_2_7_40_2 e_1_2_7_46_2 e_1_2_7_27_2 e_1_2_7_29_2 e_1_2_7_24_2 e_1_2_7_30_2 e_1_2_7_22_2 e_1_2_7_32_2 e_1_2_7_20_2 e_1_2_7_34_2 Zhou JT (e_1_2_7_42_2) 2006; 86 e_1_2_7_36_2 e_1_2_7_38_2 Seufferlein T (e_1_2_7_12_2) 1996; 56 |
References_xml | – volume: 8 start-page: 1344 year: 2009 end-page: 1351 article-title: Growth controls connect: interactions between c‐myc and the tuberous sclerosis complex‐mTOR pathway publication-title: Cell Cycle. – volume: 15 start-page: 6008 year: 2009 end-page: 6017 article-title: Spectrum of phosphatidylinositol 3‐kinase pathway gene alterations in bladder cancer publication-title: Clin Cancer Res. – volume: 59 start-page: 3245 year: 1999 end-page: 3250 article-title: Loss of P27Kip1 expression correlates with tumor grade and with reduced disease‐free survival in primary superficial bladder cancers publication-title: Cancer Res. – volume: 86 start-page: 1970 year: 2006 end-page: 1974 article-title: Expression of hypoxia inducible factor‐1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof publication-title: Zhonghua Yi Xue Za Zhi. – volume: 29 start-page: 311 year: 2008 end-page: 322 article-title: Current status of prognostic immunohistochemical markers for urothelial bladder cancer publication-title: Tumour Biol. – volume: 19 start-page: 238 year: 2006 end-page: 245 article-title: The akt pathway in human breast cancer: a tissue‐array‐based analysis publication-title: Mod Pathol. – volume: 110 start-page: 163 year: 2002 end-page: 175 article-title: mTOR interacts with raptor to form a nutrient‐sensitive complex that signals to the cell growth machinery publication-title: Cell. – volume: 23 start-page: 7378 year: 2004 end-page: 7390 article-title: Prolactin induces c‐myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells publication-title: Oncogene. – volume: 41 start-page: 619 year: 2009 end-page: 624 article-title: Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate publication-title: Nat Genet. – volume: 14 start-page: 909 year: 2005 end-page: 913 article-title: Expression of HIF‐1alpha and glut‐1 in human bladder cancer publication-title: Oncol Rep. – volume: 100 start-page: 259 year: 2007 end-page: 263 article-title: Prognostic significance of p27(Kip1) expression in bladder cancer publication-title: BJU Int. – volume: 8 start-page: 851 year: 2008 end-page: 864 article-title: Hypoxia signalling through mTOR and the unfolded protein response in cancer publication-title: Nat Rev Cancer. – volume: 1784 start-page: 150 year: 2008 end-page: 158 article-title: PI3K/PTEN signaling in tumorigenesis and angiogenesis publication-title: Biochim Biophys Acta. – volume: 56 start-page: 3895 year: 1996 end-page: 3897 article-title: Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells publication-title: Cancer Res. – volume: 18 start-page: 1 year: 2008 end-page: 8 article-title: Molecular markers in bladder cancer publication-title: Curr Opin Urol. – volume: 56 start-page: 6 year: 2009 end-page: 10 article-title: Rapamycin inhibits growth of cholangiocarcinoma cells publication-title: Hepatogastroenterology. – volume: 28 start-page: 1594 year: 2009 end-page: 1604 article-title: The role of the birt‐hogg‐dube protein in mTOR activation and renal tumorigenesis publication-title: Oncogene. – volume: 6 start-page: 729 year: 2006 end-page: 734 article-title: mTOR and cancer: insights into a complex relationship publication-title: Nat Rev Cancer. – volume: 218 start-page: 154 year: 2008 end-page: 165 article-title: Molecular alterations associated with bladder cancer initiation and progression publication-title: Scand J Urol Nephrol Suppl. – volume: 69 start-page: 8256 year: 2009 end-page: 8264 article-title: Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models publication-title: Cancer Res. – volume: 5 start-page: 713 year: 2005 end-page: 725 article-title: Urothelial tumorigenesis: a tale of divergent pathways publication-title: Nat Rev Cancer. – volume: 90 start-page: 1543 year: 2004 end-page: 1550 article-title: Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node‐negative premenopausal early breast cancer patients publication-title: Br J Cancer. – volume: 27 start-page: 255 year: 2010 end-page: 261 article-title: The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma publication-title: Med Oncol. – volume: 450 start-page: 321 year: 2007 end-page: 328 article-title: Co‐expression of EGF receptor, TGFalpha and S6 kinase is significantly associated with colorectal carcinomas with distant metastases at diagnosis publication-title: Virchows Arch. – volume: 22 start-page: S70 year: 2009 end-page: S95 article-title: Staging and reporting of urothelial carcinoma of the urinary bladder publication-title: Mod Pathol. – volume: 46 start-page: 200 year: 2004 end-page: 208 article-title: Hypoxia‐inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer publication-title: Eur Urol. – volume: 93 start-page: 143 year: 2004 end-page: 150 article-title: The phosphatidylinositol‐3 kinase pathway regulates bladder cancer cell invasion publication-title: BJU Int. – volume: 1 start-page: 394 year: 2002 end-page: 400 article-title: Understanding p27(kip1) deregulation in cancer: Down‐regulation or mislocalization publication-title: Cell Cycle. – volume: 61 start-page: 658 year: 2008 end-page: 664 article-title: Hypoxia‐inducible factor‐1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma publication-title: J Clin Pathol. – volume: 103 start-page: 89 year: 2005 end-page: 101 article-title: Practical methods for tissue microarray construction publication-title: Methods Mol Med. – volume: 66 start-page: 1929 year: 2006 end-page: 1939 article-title: Pten deficiency activates distinct downstream signaling pathways in a tissue‐specific manner publication-title: Cancer Res. – volume: 26 start-page: 3955 year: 2006 end-page: 3965 article-title: Hypoxia inhibits protein synthesis through a 4E‐BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells publication-title: Mol Cell Biol. – volume: 19 start-page: 666 year: 2001 end-page: 675 article-title: Radical cystectomy in the treatment of invasive bladder cancer: long‐term results in 1,054 patients publication-title: J Clin Oncol. – volume: 38 start-page: 195 year: 2008 end-page: 209 article-title: Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF‐kappaB pathways in human gastric adenocarcinoma publication-title: Ann Clin Lab Sci. – volume: 446 start-page: 55 year: 1999 end-page: 59 article-title: Hypoxia increases the association of 4E‐binding protein 1 with the initiation factor 4E in isolated rat hepatocytes publication-title: FEBS Lett. – volume: 107 start-page: 1801 year: 2006 end-page: 1811 article-title: Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer publication-title: Cancer. – volume: 18 start-page: 1926 year: 2004 end-page: 1945 article-title: Upstream and downstream of mTOR publication-title: Genes Dev. – volume: 37 start-page: 217 year: 2009 end-page: 222 article-title: A complex interplay between akt, TSC2 and the 2 mTOR complexes publication-title: Biochem Soc Trans. – volume: 10 start-page: 8421 year: 2004 end-page: 8425 article-title: mTOR and P70 S6 kinase expression in primary liver neoplasms publication-title: Clin Cancer Res. – volume: 47 start-page: 678 year: 2008 end-page: 685 article-title: Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray publication-title: Mol Carcinog. – volume: 29 start-page: 399 year: 2009 end-page: 405 article-title: Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin‐resected hepatocellular carcinoma publication-title: Liver Int. – volume: 183 start-page: 68 year: 2010 end-page: 75 article-title: Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer publication-title: J Urol. – volume: 41 start-page: 524 year: 2009 end-page: 526 article-title: Cooperativity of TMPRSS2‐ERG with PI3‐kinase pathway activation in prostate oncogenesis publication-title: Nat Genet. – volume: 23 start-page: 675 year: 2009 end-page: 680 article-title: Inactivation of p53 and pten promotes invasive bladder cancer publication-title: Genes Dev. – volume: 77 start-page: 255 year: 2006 end-page: 263 article-title: Hypoxia‐inducible factors HIF‐1alpha and HIF‐2alpha expression in bladder cancer and their associations with other angiogenesis‐related proteins publication-title: Urol Int. – volume: 177 start-page: 481 year: 2007 end-page: 487 article-title: Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. publication-title: J Urol. – volume: 50 start-page: 77 year: 2003 end-page: 83 article-title: Increased expression of phosphorylated p70S6 kinase and akt in papillary thyroid cancer tissues publication-title: Endocr J. – volume: 109 start-page: 2257 year: 2007 end-page: 2267 article-title: Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy publication-title: Cancer. – volume: 75 start-page: 102 year: 2005 end-page: 106 article-title: Differential PTEN protein expression profiles in superficial versus invasive bladder cancers publication-title: Urol Int. – ident: e_1_2_7_45_2 doi: 10.1016/j.eururo.2004.04.008 – volume: 59 start-page: 3245 year: 1999 ident: e_1_2_7_48_2 article-title: Loss of P27Kip1 expression correlates with tumor grade and with reduced disease‐free survival in primary superficial bladder cancers publication-title: Cancer Res. contributor: fullname: Sgambato A – ident: e_1_2_7_16_2 doi: 10.1002/cncr.22195 – ident: e_1_2_7_26_2 doi: 10.1111/j.1464-410X.2004.04574.x – volume: 56 start-page: 6 year: 2009 ident: e_1_2_7_18_2 article-title: Rapamycin inhibits growth of cholangiocarcinoma cells publication-title: Hepatogastroenterology. contributor: fullname: Okada T – ident: e_1_2_7_43_2 doi: 10.1159/000094819 – ident: e_1_2_7_13_2 doi: 10.1007/s00428-007-0370-2 – ident: e_1_2_7_4_2 doi: 10.1042/BST0370217 – ident: e_1_2_7_28_2 doi: 10.1038/ng.371 – ident: e_1_2_7_19_2 doi: 10.1007/s12032-009-9201-4 – volume: 38 start-page: 195 year: 2008 ident: e_1_2_7_14_2 article-title: Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF‐kappaB pathways in human gastric adenocarcinoma publication-title: Ann Clin Lab Sci. contributor: fullname: Feng W – ident: e_1_2_7_47_2 doi: 10.1111/j.1464-410X.2007.06927.x – ident: e_1_2_7_36_2 doi: 10.1016/S0092-8674(02)00808-5 – ident: e_1_2_7_24_2 doi: 10.1038/nrc1697 – ident: e_1_2_7_23_2 doi: 10.1097/MOU.0b013e3282f1c5c1 – ident: e_1_2_7_8_2 doi: 10.1038/nrc1974 – ident: e_1_2_7_37_2 doi: 10.1038/nrc2501 – ident: e_1_2_7_6_2 doi: 10.4161/cc.1.6.263 – volume: 56 start-page: 3895 year: 1996 ident: e_1_2_7_12_2 article-title: Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells publication-title: Cancer Res. contributor: fullname: Seufferlein T – ident: e_1_2_7_21_2 doi: 10.1038/sj.bjc.6601741 – ident: e_1_2_7_40_2 doi: 10.1101/gad.1212704 – ident: e_1_2_7_2_2 doi: 10.1200/JCO.2001.19.3.666 – ident: e_1_2_7_31_2 doi: 10.1158/0008-5472.CAN-09-1689 – ident: e_1_2_7_38_2 doi: 10.1128/MCB.26.10.3955-3965.2006 – ident: e_1_2_7_3_2 doi: 10.1080/03008880802291915 – ident: e_1_2_7_15_2 doi: 10.1038/onc.2009.14 – ident: e_1_2_7_27_2 doi: 10.1002/mc.20420 – ident: e_1_2_7_30_2 doi: 10.1002/cncr.22677 – ident: e_1_2_7_20_2 doi: 10.1111/j.1478-3231.2008.01798.x – ident: e_1_2_7_50_2 doi: 10.1159/000170878 – ident: e_1_2_7_25_2 doi: 10.1158/1078-0432.CCR-09-0898 – volume: 103 start-page: 89 year: 2005 ident: e_1_2_7_10_2 article-title: Practical methods for tissue microarray construction publication-title: Methods Mol Med. contributor: fullname: Fedor HL – volume: 86 start-page: 1970 year: 2006 ident: e_1_2_7_42_2 article-title: Expression of hypoxia inducible factor‐1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof publication-title: Zhonghua Yi Xue Za Zhi. contributor: fullname: Zhou JT – ident: e_1_2_7_34_2 doi: 10.1159/000085933 – ident: e_1_2_7_46_2 doi: 10.4161/cc.8.9.8215 – ident: e_1_2_7_41_2 doi: 10.1136/jcp.2007.050666 – ident: e_1_2_7_29_2 doi: 10.1038/ng.370 – ident: e_1_2_7_33_2 doi: 10.1101/gad.1772909 – ident: e_1_2_7_49_2 doi: 10.1016/j.juro.2006.09.038 – ident: e_1_2_7_22_2 doi: 10.1016/j.juro.2009.08.115 – ident: e_1_2_7_32_2 doi: 10.1158/0008-5472.CAN-05-1986 – ident: e_1_2_7_9_2 doi: 10.1038/modpathol.2009.1 – ident: e_1_2_7_7_2 doi: 10.1038/sj.onc.1208002 – ident: e_1_2_7_11_2 doi: 10.1507/endocrj.50.77 – ident: e_1_2_7_5_2 doi: 10.1016/j.bbapap.2007.09.008 – ident: e_1_2_7_39_2 doi: 10.1016/S0014-5793(99)00185-4 – ident: e_1_2_7_17_2 doi: 10.1158/1078-0432.CCR-04-0941 – ident: e_1_2_7_35_2 doi: 10.1038/modpathol.3800525 – volume: 14 start-page: 909 year: 2005 ident: e_1_2_7_44_2 article-title: Expression of HIF‐1alpha and glut‐1 in human bladder cancer publication-title: Oncol Rep. contributor: fullname: Palit V |
SSID | ssj0007253 |
Score | 2.318718 |
Snippet | BACKGROUND:
Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is... Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial.... Abstract BACKGROUND: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of... BACKGROUND: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is... BACKGROUNDBladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is... |
SourceID | proquest crossref pubmed pascalfrancis wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 5517 |
SubjectTerms | 4E‐BP1 Aged Akt Biological and medical sciences Biomarkers, Tumor - metabolism bladder Cancer Cystectomy c‐myc Female Histology Humans lymph nodes Male mammalian target of rapamycin Medical sciences Middle Aged migration Morbidity Mortality Nephrology. Urinary tract diseases p27 phosS6 Prognosis Pten Signal Transduction survival Tissue Array Analysis TOR Serine-Threonine Kinases - metabolism Tumors Tumors of the urinary system urinary bladder Urinary Bladder Neoplasms - metabolism Urinary Bladder Neoplasms - surgery Urinary tract. Prostate gland urothelial carcinoma Urothelium |
Title | Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.25502 https://www.ncbi.nlm.nih.gov/pubmed/20939013 https://search.proquest.com/docview/1017960769 https://search.proquest.com/docview/812130296 |
Volume | 116 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB5CDqFQ-n64TYNKeyp445Ut2YZcwpIQCskhNLCXYkavS2M7rNe025_SX1uN7N1lS1tob0LoYUkzo8_S6BuA95k0uRFTFxcGKYSZ0TGWOcbCcuf8fiG5pR_Fyyt5cZN9nIv5Hpys38IM_BCbAzfSjGCvScFRdcdb0lDd6MXEA-LAJElMeoSIrrfcUTkfKSiTIhZZOt9wk_LjbdWd3ej-HXZ-YtwQ0eJ3kHMXwYYt6PwhfF5__OB58mXSL9VEf_-F1_F_R_cIHozYlJ0OwvQY9mzzBA4ux9v3p_Dj7NvoNtsweojUdwwbw8jFq2mJ75mRNwj5HpEosdaxGus6HKSwweOc8ijker3yLTKKhvwVV6y2FJWkYz6rX9CLMF_jlmmKctS0NVIluhPwg2HqlizlgoXQ5kwTDbVetvXqGdycn32aXcRjbIdYZx4yxqoosbAevTmDMk-EQRR2KpVJ0aeMRTe1RWKx5K4QqD2qnlqPnaRRTpZWZ-lz2G_axr4EJnNrM5MpctbNfGsKLedJYYVTXHnzFMG79RpXdwOFRzWQNfOKprkK0xzB0c7yb4rylFjQpIjg7VoeKq-CdK-CjW37rgpWTSa--wjYH8oURJ2X8FJG8GKQpW0HSUkHT2kEH4JE_OUjq9nV7DqkXv1L4ddwj2-8cA5hf7no7RuPpZbqKOjMT0FJH_M |
link.rule.ids | 315,786,790,1382,27955,27956,46327,46751 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwGP2EhgRIiDssXIYRPCGlS53YSR5R2VRg7cO0SX2LfH1hcaam0Sg_hV-LPydrVQRI8BZFdi7O99kn9vE5AO8yrnPNxjYutEALM61iUeYiZoZa68cLTg3-KM7mfHqefV6wxcDNwb0wvT7EZsINMyP015jgOCF9uFUNVU4tRx4Ro5TkTZ_vDPPy4-lWPSqngwhlUsQsSxcbdVJ6uK27Mx7dvRStbxrbe1r8DnTuYtgwCB3f751W26BdiNyTr6NuJUfq-y_Kjv_9fg_g3gBPyYc-nh7CDeMewa3ZsAD_GH4cfRuYs47gXqSuJcJpgiwv16DkM0FCCNKPMJpIY0kt6jrMpZCedI7n0HW9XvsrEjREvhJrUhs0JmmJP9UtcVOYr3FBFBoduaYWWAmXBfzbEHmBneWSBHdzolCJWq2aev0Ezo-PzibTeLB3iFXmUWMsi1IUxgM4qwXPE6aFYGbMpU6FP9JG2LEpEiNKagsmlAfWY-PhE9fS8tKoLH0Ke65xZh8Iz43JdCaRr5v5q0lhKE0Kw6yk0vdQEby9_sjVZa_iUfV6zbTCZq5CM0dwsPP9N0VpikJonEXw5jogKp-FuLQinGm6tgodG0_87SMgfyhToHpeQksewbM-mLY3SEqce0ojeB9C4i8PWU3mk9Nw9PxfCr-G29Oz2Ul18mn-5QXcoRtSzkvYWy0788pDq5U8CAn0EyIgJBM |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bixMxFD4sKyyCeHcdL2tEn4TpTjOTzAz4It0t62WLLC70RYZcX9zJlLaD1p_irzUnM22pqKBvIeSec5Ivycl3AF5mXOeaDW1caIEuzLSKRZmLmBlqrd8vODV4UDyf8LPL7N2UTffg9fovTMcPsblwQ80I6zUq-Ezb4y1pqHJqPvCAGJkkr2U8pXj0OrnYkkfltOegTIqYZel0Q05Kj7d5d7ajGzOx8CNjO5cWv8OcuxA27EHjW_B53frO9OTLoF3Kgfr-C7Hj_3bvNtzswSl500nTHdgz7i4cnPfP7_fgx-m33m7WEfyJ1C6IcJqgjZdrkPCZoDkIGh-hLJHGklrUdbhJIZ3JOcahz_V65Usk6A75q1iR2qBbkgXxUe0cv4T5HFdEoZsj19QCM-GjgO8MkVe4VM5J8G1OFPJQq2VTr-7D5fj00-gs7p07xCrzmDGWRSkK4-Gb1YLnCdNCMDPkUqfCh7QRdmiKxIiS2oIJ5WH10HjwxLW0vDQqSx_AvmuceQiE58ZkOpNorZv50qQwlCaFYVZS6denCF6s57iadRweVcfWTCsc5ioMcwRHO9O_SUpTpEHjLILna3movA7iw4pwpmkXVVjWeOKrj4D8IU2B3HkJLXkEh50sbStISrx5SiN4FSTiL42sRpPRRQg9-pfEz-Dg48m4-vB28v4xXKcbi5wnsL-ct-apx1VLeRTU5yeulyLC |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Expression+status+and+prognostic+significance+of+mammalian+target+of+rapamycin+pathway+members+in+urothelial+carcinoma+of+urinary+bladder+after+cystectomy&rft.jtitle=Cancer&rft.au=Schultz%2C+Luciana&rft.au=Albadine%2C+Roula&rft.au=Hicks%2C+Jessica&rft.au=Jadallah%2C+Sana&rft.date=2010-12-01&rft.issn=1097-0142&rft.volume=116&rft.issue=23&rft.spage=5517&rft.epage=5526&rft_id=info:doi/10.1002%2Fcncr.25502&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |